Discover Community Create You

Loading publication...

Noodle always counts identifier-free feature events for service operation. With your permission, Google Analytics can also estimate audience and engagement. Search text, publication identifiers, cookies, IP addresses and browser fingerprints are never included in Noodle's first-party event counters.

Privacy details

Article

Anti-CD19/CD20 bispecific antibody with dual Fc domains mediates enhanced effector functions and durable depletion of memory B cells in vivo

27 Aug 2025

Abstract excerpt

Recent clinical studies suggest that more potent B cell depleting therapies and targeting more than one B cell antigen may result in improved clinical responses in autoimmune diseases and hematological malignancies. Here we describe an anti-CD19/CD20 bispecific antibody, HB2198, generated using GEM-DIMER™ technology. HB2198 incorporates Fab domains from rituximab and humanized FMC63 (huFMC63) for bivalent binding...

Read the complete abstract on PubMed

Topics

Share this publication in a Topic to start or enrich a Post.

Share to CAR-T cell therapy research
Share to Monoclonal and Polyclonal Antibodies Research
Share to T-cell and B-cell Immunology

Methodology Data sources Editorial policy Privacy About Contact Helena Bioinformatics

Source

Identifiers

PMID: 40866422
DOI: 10.1038/s41598-025-16461-z

Provenance

PubMed metadata and Literature Corpus relationships. Corpus snapshot updated 6 Sept 2026.

Related research

Semantic proximity does not establish scientific evidence.

Research trail→

Click a neighbor to travelStep 1 · 12 closest

Anti-CD19/CD20 bispecific antibody with dual Fc domains mediates enhanced effector functions and durable depletion of memory B cells in vivoPMID 40866422Read ↗

Bispecific CD20xCD40 Antibodies Achieve Multi-Lineage Modulation of Humoral and Cellular ImmunitySemantic proximity Read ↗

A novel, native-format bispecific antibody triggering T-cell killing of B-cells is robustly active in mouse tumor models and cynomolgus monkeys.Semantic proximity Read ↗

A computationally designed Rituximab/CD3 T cell engager targeting CD20+ cancers with multiple mechanisms of actionSemantic proximity Read ↗

Mechanism of Action and Pharmacokinetics of Approved Bispecific AntibodiesSemantic proximity Read ↗

DuoBody-CD3xCD20 induces potent T-cell-mediated killing of malignant B cells in preclinical models and provides opportunities for subcutaneous dosing.Semantic proximity Read ↗

GPR183 mediates the capacity of the novel CD47-CD19 bispecific antibody TG-1801 to heighten ublituximab-umbralisib (U2) anti-lymphoma activitySemantic proximity Read ↗

Efficient production of bispecific IgG of different isotypes and species of origin in single mammalian cellsSemantic proximity Read ↗

Bispecific antibody target pair discovery by high-throughput phenotypic screening using in vitro combinatorial Fab librariesSemantic proximity Read ↗

In vitro effects of rituximab on the proliferation, activation and differentiation of human B cells.Semantic proximity Read ↗

A CHIMERIC RECEPTOR ENABLING ANTIBODY-GUIDED RETARGETING OF CAR T- CELLSSemantic proximity Read ↗

Cellular Cytotoxicity of Next-Generation CD20 Monoclonal AntibodiesSemantic proximity Read ↗

Exploring CAR T-Cell Dynamics: Balancing Potent Cytotoxicity and Controlled Inflammation in CAR T-Cells Derived from Systemic Sclerosis and Myositis PatientsSemantic proximity Read ↗

⌁Select a neighboring publication to make it the new centre.